ALK and non-small cell lung carcinoma: Lorlatinib has shown marked systemic and intracranial activity in patients with ALK-positive advanced NSCLC who were treatment-naive or who had progressed on a range of prior ALK-TKIs (Shaw et al., 2017; Shaw et al., 2020).